<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Potrekar, Ravindra</style></author><author><style face="normal" font="default" size="100%">Kulkarni, R. A.</style></author><author><style face="normal" font="default" size="100%">Vernekar, S. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthesis and characterization of novel polybenzimidazoles bearing pendant phenoxyamine groups</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Polymer Science Part A-Polymer Chemistry</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Characterization</style></keyword><keyword><style  face="normal" font="default" size="100%">copolybenzimidazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">High performance polymers</style></keyword><keyword><style  face="normal" font="default" size="100%">high temperature materials</style></keyword><keyword><style  face="normal" font="default" size="100%">pendant phenoxyamine group</style></keyword><keyword><style  face="normal" font="default" size="100%">polybenzimidazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">synthesis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">SEP</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">17</style></number><publisher><style face="normal" font="default" size="100%">JOHN WILEY &amp; SONS INC</style></publisher><pub-location><style face="normal" font="default" size="100%">111 RIVER ST, HOBOKEN, NJ 07030 USA</style></pub-location><volume><style face="normal" font="default" size="100%">46</style></volume><pages><style face="normal" font="default" size="100%">5776-5793</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A novel aromatic diacid, 3, 5-dicarboxyl-4'-amino diphenyl ether, containing pendant phenoxy amine group was synthesized. Homo- and co-polybenzimidazoles containing different content of pendant phenoxyamine groups were synthesized by condensation of 3,3'-diaminobenzidine with this acid and a mixture of this acid and isophthalic acid in different ratio in polyphosphoric acid. Copolybenzimidazoles with structural variations were also synthesized based on this acid and pyridine dicarboxylic acid, terephthalic acid, adipic acid, or sebacic acid. The polymers have good solubility in polar aprotic solvents and strong acids and they form tough flexible films by solution casting. The polymers were characterized by different instrumental techniques (FTIR, TGA, DSC, XRD, etc.) and for solvent solubility, mechanical properties, inherent viscosity, and proton conductivity. The inherent viscosities of the polymers vary in the range of 0.62-1.52 dL/g. They have high thermal stability up to 475506 degrees C (IDT) in nitrogen, high glass transition temperatures (T-g) ranging from 313 to 435 degrees C and good tensile strength ranging from 58 to 125 MPa. Proton conductivity of homo polymer is 3.72 x 10(-3) S/cm at 25 degrees C and 2.45 x 10(-2) S/cm at 200 degrees C (c) 2008 Wiley Periodicals, Inc.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">17</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">3.114</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Potrekar, Ravindra</style></author><author><style face="normal" font="default" size="100%">Kulkarni, R. A.</style></author><author><style face="normal" font="default" size="100%">Vernekar, S. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nitrophenoxy groups containing polybenzimidazoles as polymer electrolytes for fuel cells: synthesis and characterization</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Applied Polymer Science</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Characterization</style></keyword><keyword><style  face="normal" font="default" size="100%">membranes</style></keyword><keyword><style  face="normal" font="default" size="100%">pendant nitrophenoxy group</style></keyword><keyword><style  face="normal" font="default" size="100%">polybenzimidazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">proton conductivity</style></keyword><keyword><style  face="normal" font="default" size="100%">synthesis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">SEP</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">6</style></number><publisher><style face="normal" font="default" size="100%">JOHN WILEY &amp; SONS INC</style></publisher><pub-location><style face="normal" font="default" size="100%">111 RIVER ST, HOBOKEN, NJ 07030 USA</style></pub-location><volume><style face="normal" font="default" size="100%">117</style></volume><pages><style face="normal" font="default" size="100%">3282-3292</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Polybenzimidazoles containing different contents of pendant nitrophenoxy groups were prepared by condensation of 3,3'-diamino-benzidine with a mixture of 3,5-dicarboxyl-4'-nitro diphenyl ether and isophthalic acid (IPA) in different ratios in polyphosphoric acid. The polymers are soluble in polar aprotic solvents, they have inherent viscosities in the range of 0.75-1.10 dL g(-1) and they form tough and transparent films on solution casting. They have good thermal stability with initial decomposition temperature ranging from 380 to 416 degrees C in nitrogen, good tensile strength ranging from 56 to 65 MPa and reasonably good oxidative stability. Phosphoric acid uptake of these polymers is low compared with PBI and membranes doped with phosphoric acid exhibit good proton conductivity in the range of 6.6x 10(-3) to 1.9x 10(-2) S/cm at 25 degrees C and 1.2x 10(-2) to 4.9x 10(-2) S/cm at 175 degrees C, compared with 3.9x 10(-3) S/cm at 25 degrees C and 3.2x 10(-2) S/cm at 175 degrees C for PBI. These membranes are suitable for applications as polymer electrolyte for fuel cell and presumably for gas separation at high temperature. (C) 2010 Wiley Periodicals, Inc. J Appl Polym Sci 117: 3282-3292, 2010&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">1.240</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naushin, Salwa</style></author><author><style face="normal" font="default" size="100%">Sardana, Viren</style></author><author><style face="normal" font="default" size="100%">Ujjainiya, Rajat</style></author><author><style face="normal" font="default" size="100%">Bhatheja, Nitin</style></author><author><style face="normal" font="default" size="100%">Kutum, Rintu</style></author><author><style face="normal" font="default" size="100%">Bhaskar, Akash Kumar</style></author><author><style face="normal" font="default" size="100%">Pradhan, Shalini</style></author><author><style face="normal" font="default" size="100%">Prakash, Satyartha</style></author><author><style face="normal" font="default" size="100%">Khan, Raju</style></author><author><style face="normal" font="default" size="100%">Rawat, Birendra Singh</style></author><author><style face="normal" font="default" size="100%">Tallapaka, Karthik Bharadwaj</style></author><author><style face="normal" font="default" size="100%">Anumalla, Mahesh</style></author><author><style face="normal" font="default" size="100%">Chandak, Giriraj Ratan</style></author><author><style face="normal" font="default" size="100%">Lahiri, Amit</style></author><author><style face="normal" font="default" size="100%">Kar, Susanta</style></author><author><style face="normal" font="default" size="100%">Mulay, Shrikant Ramesh</style></author><author><style face="normal" font="default" size="100%">Mugale, Madhav Nilakanth</style></author><author><style face="normal" font="default" size="100%">Srivastava, Mrigank</style></author><author><style face="normal" font="default" size="100%">Khan, Shaziya</style></author><author><style face="normal" font="default" size="100%">Srivastava, Anjali</style></author><author><style face="normal" font="default" size="100%">Tomar, Bhawana</style></author><author><style face="normal" font="default" size="100%">Veerapandian, Murugan</style></author><author><style face="normal" font="default" size="100%">Venkatachalam, Ganesh</style></author><author><style face="normal" font="default" size="100%">Vijayakumar, Selvamani Raja</style></author><author><style face="normal" font="default" size="100%">Agarwal, Ajay</style></author><author><style face="normal" font="default" size="100%">Gupta, Dinesh</style></author><author><style face="normal" font="default" size="100%">Halami, Prakash M.</style></author><author><style face="normal" font="default" size="100%">Peddha, Muthukumar Serva</style></author><author><style face="normal" font="default" size="100%">Sundaram, Gopinath M.</style></author><author><style face="normal" font="default" size="100%">Veeranna, Ravindra P.</style></author><author><style face="normal" font="default" size="100%">Pal, Anirban</style></author><author><style face="normal" font="default" size="100%">Agarwal, Vinay Kumar</style></author><author><style face="normal" font="default" size="100%">Maurya, Anil Ku</style></author><author><style face="normal" font="default" size="100%">Singh, Ranvijay Kumar</style></author><author><style face="normal" font="default" size="100%">Raman, Ashok Kumar</style></author><author><style face="normal" font="default" size="100%">Anandasadagopan, Suresh Kumar</style></author><author><style face="normal" font="default" size="100%">Karuppanan, Parimala</style></author><author><style face="normal" font="default" size="100%">Venkatesan, Subramanian</style></author><author><style face="normal" font="default" size="100%">Sardana, Harish Kumar</style></author><author><style face="normal" font="default" size="100%">Kothari, Anamika</style></author><author><style face="normal" font="default" size="100%">Jain, Rishabh</style></author><author><style face="normal" font="default" size="100%">Thakur, Anupama</style></author><author><style face="normal" font="default" size="100%">Parihar, Devendra Singh</style></author><author><style face="normal" font="default" size="100%">Saifi, Anas</style></author><author><style face="normal" font="default" size="100%">Kaur, Jasleen</style></author><author><style face="normal" font="default" size="100%">Kumar, Virendra</style></author><author><style face="normal" font="default" size="100%">Mishra, Avinash</style></author><author><style face="normal" font="default" size="100%">Gogeri, Iranna</style></author><author><style face="normal" font="default" size="100%">Rayasam, Geethavani</style></author><author><style face="normal" font="default" size="100%">Singh, Praveen</style></author><author><style face="normal" font="default" size="100%">Chakraborty, Rahul</style></author><author><style face="normal" font="default" size="100%">Chaturvedi, Gaura</style></author><author><style face="normal" font="default" size="100%">Karunakar, Pinreddy</style></author><author><style face="normal" font="default" size="100%">Yadav, Rohit</style></author><author><style face="normal" font="default" size="100%">Singhmar, Sunanda</style></author><author><style face="normal" font="default" size="100%">Singh, Dayanidhi</style></author><author><style face="normal" font="default" size="100%">Sarkar, Sharmistha</style></author><author><style face="normal" font="default" size="100%">Bhattacharya, Purbasha</style></author><author><style face="normal" font="default" size="100%">Acharya, Sundaram</style></author><author><style face="normal" font="default" size="100%">Singh, Vandana</style></author><author><style face="normal" font="default" size="100%">Verma, Shweta</style></author><author><style face="normal" font="default" size="100%">Soni, Drishti</style></author><author><style face="normal" font="default" size="100%">Seth, Surabhi</style></author><author><style face="normal" font="default" size="100%">Vashisht, Sakshi</style></author><author><style face="normal" font="default" size="100%">Thakran, Sarita</style></author><author><style face="normal" font="default" size="100%">Fatima, Firdaus</style></author><author><style face="normal" font="default" size="100%">Singh, Akash Pratap</style></author><author><style face="normal" font="default" size="100%">Sharma, Akanksha</style></author><author><style face="normal" font="default" size="100%">Sharma, Babita</style></author><author><style face="normal" font="default" size="100%">Subramanian, Manikandan</style></author><author><style face="normal" font="default" size="100%">Padwad, Yogendra S.</style></author><author><style face="normal" font="default" size="100%">Hallan, Vipin</style></author><author><style face="normal" font="default" size="100%">Patial, Vikram</style></author><author><style face="normal" font="default" size="100%">Singh, Damanpreet</style></author><author><style face="normal" font="default" size="100%">Tripude, Narendra Vijay</style></author><author><style face="normal" font="default" size="100%">Chakrabarti, Partha</style></author><author><style face="normal" font="default" size="100%">Maity, Sujay Krishna</style></author><author><style face="normal" font="default" size="100%">Ganguly, Dipyaman</style></author><author><style face="normal" font="default" size="100%">Sarkar, Jit</style></author><author><style face="normal" font="default" size="100%">Ramakrishna, Sistla</style></author><author><style face="normal" font="default" size="100%">Kumar, Balthu Narender</style></author><author><style face="normal" font="default" size="100%">Kumar, Kiran A.</style></author><author><style face="normal" font="default" size="100%">Gandhi, Sumit G.</style></author><author><style face="normal" font="default" size="100%">Jamwal, Piyush Singh</style></author><author><style face="normal" font="default" size="100%">Chouhan, Rekha</style></author><author><style face="normal" font="default" size="100%">Jamwal, Vijay Lakshmi</style></author><author><style face="normal" font="default" size="100%">Kapoor, Nitika</style></author><author><style face="normal" font="default" size="100%">Ghosh, Debashish</style></author><author><style face="normal" font="default" size="100%">Thakkar, Ghanshyam</style></author><author><style face="normal" font="default" size="100%">Subudhi, Umakanta</style></author><author><style face="normal" font="default" size="100%">Sen, Pradip</style></author><author><style face="normal" font="default" size="100%">Chaudhury, Saumya Ray</style></author><author><style face="normal" font="default" size="100%">Kumar, Rashmi</style></author><author><style face="normal" font="default" size="100%">Gupta, Pawan</style></author><author><style face="normal" font="default" size="100%">Tuli, Amit</style></author><author><style face="normal" font="default" size="100%">Sharma, Deepak</style></author><author><style face="normal" font="default" size="100%">Ringe, Rajesh P.</style></author><author><style face="normal" font="default" size="100%">Amarnarayan, D.</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Shanmugam, Dhansekaran</style></author><author><style face="normal" font="default" size="100%">Dharne, Mahesh S.</style></author><author><style face="normal" font="default" size="100%">Dastager, Sayed G.</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Patil, Amita P.</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin N.</style></author><author><style face="normal" font="default" size="100%">Khan, Abujunaid Habib</style></author><author><style face="normal" font="default" size="100%">Wagh, Vasudev</style></author><author><style face="normal" font="default" size="100%">Yadav, Rakesh Kumar</style></author><author><style face="normal" font="default" size="100%">Khilari, Ajinkya</style></author><author><style face="normal" font="default" size="100%">Bhadange, Mayuri</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Arvindkumar H.</style></author><author><style face="normal" font="default" size="100%">Kulsange, Shabda E.</style></author><author><style face="normal" font="default" size="100%">Khairnar, Krishna</style></author><author><style face="normal" font="default" size="100%">Paranjape, Shilpa</style></author><author><style face="normal" font="default" size="100%">Kalita, Jatin</style></author><author><style face="normal" font="default" size="100%">Sastry, Narahari G.</style></author><author><style face="normal" font="default" size="100%">Phukan, Tridip</style></author><author><style face="normal" font="default" size="100%">Manna, Prasenjit</style></author><author><style face="normal" font="default" size="100%">Romi, Wahengbam</style></author><author><style face="normal" font="default" size="100%">Bharali, Pankaj</style></author><author><style face="normal" font="default" size="100%">Ozah, Dibyajyoti</style></author><author><style face="normal" font="default" size="100%">Sahu, Ravi Kumar</style></author><author><style face="normal" font="default" size="100%">Babu, Elapavalooru Vssk</style></author><author><style face="normal" font="default" size="100%">Sukumaran, Rajeev</style></author><author><style face="normal" font="default" size="100%">Nair, Aiswarya R.</style></author><author><style face="normal" font="default" size="100%">Valappil, Prajeesh Kooloth</style></author><author><style face="normal" font="default" size="100%">Puthiyamadam, Anoop</style></author><author><style face="normal" font="default" size="100%">Velayudhanpillai, Adarsh</style></author><author><style face="normal" font="default" size="100%">Chodankar, Kalpana</style></author><author><style face="normal" font="default" size="100%">Damare, Samir</style></author><author><style face="normal" font="default" size="100%">Madhavi, Yennapu</style></author><author><style face="normal" font="default" size="100%">Aggarwal, Ved Varun</style></author><author><style face="normal" font="default" size="100%">Dahiya, Sumit</style></author><author><style face="normal" font="default" size="100%">Agrawal, Anurag</style></author><author><style face="normal" font="default" size="100%">Dash, Debasis</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shantanu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Insights from a pan India Sero-epidemiological survey (Phenome-India Cohort) for SARS-CoV2</style></title><secondary-title><style face="normal" font="default" size="100%">eLife</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">APR </style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">e66537</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, &amp;lt;0.0001), use of public transport (1.79, 1.43-2.24, &amp;lt;0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, &amp;lt;0.0001), and B blood group (1.36, 1.15-1.61, 0.001).&lt;/p&gt;</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">8.140</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rana, Rashmi</style></author><author><style face="normal" font="default" size="100%">Chauhan, Kirti</style></author><author><style face="normal" font="default" size="100%">Gautam, Poonam</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Banarjee, Reema</style></author><author><style face="normal" font="default" size="100%">Chugh, Parul</style></author><author><style face="normal" font="default" size="100%">Chhabra, Satnam Singh</style></author><author><style face="normal" font="default" size="100%">Acharya, Rajesh</style></author><author><style face="normal" font="default" size="100%">Kalra, Samir Kumar</style></author><author><style face="normal" font="default" size="100%">Gupta, Anshul</style></author><author><style face="normal" font="default" size="100%">Jain, Sunila</style></author><author><style face="normal" font="default" size="100%">Ganguly, Nirmal Kumar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Plasma-derived extracellular vesicles reveal galectin-3 binding protein as potential biomarker for early detection of glioma</style></title><secondary-title><style face="normal" font="default" size="100%">Frontiers in Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">blood-based biomarker</style></keyword><keyword><style  face="normal" font="default" size="100%">early detection</style></keyword><keyword><style  face="normal" font="default" size="100%">galectin-3 binding protein</style></keyword><keyword><style  face="normal" font="default" size="100%">plasma-derived extracellular vesicles</style></keyword><keyword><style  face="normal" font="default" size="100%">proteomics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">NOV 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">778754</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">{Gliomas are the most common type of the malignant brain tumor, which arise from glial cells. They make up about 40% of all primary brain tumors and around 70% of all primary malignant brain tumors. They can occur anywhere in the central nervous system (CNS) and have a poor prognosis. The average survival of glioma patients is approximately 6-15 months with poor aspects of life. In this edge, identification of proteins secreted by cancer cells is of special interest because it may provide a better understanding of tumor progression and provide early diagnosis of the diseases. Extracellular vesicles (EVs) were isolated from pooled plasma of healthy controls (n=03) and patients with different grades of glioma (Grade I or II or III</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">6.244</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patil, Gouri</style></author><author><style face="normal" font="default" size="100%">Kulsange, Shabda</style></author><author><style face="normal" font="default" size="100%">Kazi, Rubina</style></author><author><style face="normal" font="default" size="100%">Chirmade, Tejas</style></author><author><style face="normal" font="default" size="100%">Kale, Vaikhari</style></author><author><style face="normal" font="default" size="100%">Mote, Chandrashekhar</style></author><author><style face="normal" font="default" size="100%">Aswar, Manoj</style></author><author><style face="normal" font="default" size="100%">Koratkar, Santosh</style></author><author><style face="normal" font="default" size="100%">Agawane, Sachin</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Behavioral and proteomic studies reveal methylglyoxal activate pathways associated with alzheimer’s disease</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Pharmacology &amp; Translational Science</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">DEC</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">65–75</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	&lt;span style=&quot;color: rgb(0, 0, 0); font-family: georgia, serif; font-size: 17.008px; background-color: rgb(244, 244, 244);&quot;&gt;Diabetes is one of the major risk factors for Alzheimer’s disease (AD) development. The role of elevated levels of glucose, methylglyoxal (MGO), and advanced glycation end products (AGEs) in the pathogenesis of AD is not well understood. In this pursuit, we studied the role of methylglyoxal in the pathogenesis of AD in rat models. The elevated plus-maze (EPM) behavioral study indicated that MGO induces anxiety. Treatment of telmisartan (RAGE expression inhibitor) and aminoguanidine (MGO quencher) attenuated MGO induced anxiety. Further, hippocampal proteomics demonstrated that MGO treated rats differentially regulate proteins involved in calcium homeostasis, mitochondrial functioning, and apoptosis, which may affect neurotransmission and neuronal plasticity. The hippocampal tau phosphorylation level was increased in MGO treated rats, which was reduced in the presence of aminoguanidine and telmisartan. The plasma fructosamine level was increased upon MGO treatment. Hippocampal histochemistry showed vascular degeneration and neuronal loss upon MGO treatment. This study provides mechanistic insight into the role of MGO in the diabetes-associated development of AD.&lt;/span&gt;&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	NA&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, Prateek</style></author><author><style face="normal" font="default" size="100%">Ujjainiya, Rajat</style></author><author><style face="normal" font="default" size="100%">Prakash, Satyartha</style></author><author><style face="normal" font="default" size="100%">Naushin, Salwa</style></author><author><style face="normal" font="default" size="100%">Sardana, Viren</style></author><author><style face="normal" font="default" size="100%">Bhatheja, Nitin</style></author><author><style face="normal" font="default" size="100%">Singh, Ajay Pratap</style></author><author><style face="normal" font="default" size="100%">Barman, Joydeb</style></author><author><style face="normal" font="default" size="100%">Kumar, Kartik</style></author><author><style face="normal" font="default" size="100%">Gayali, Saurabh</style></author><author><style face="normal" font="default" size="100%">Khan, Raju</style></author><author><style face="normal" font="default" size="100%">Rawat, Birendra Singh</style></author><author><style face="normal" font="default" size="100%">Tallapaka, Karthik Bharadwaj</style></author><author><style face="normal" font="default" size="100%">Anumalla, Mahesh</style></author><author><style face="normal" font="default" size="100%">Lahiri, Amit</style></author><author><style face="normal" font="default" size="100%">Kar, Susanta</style></author><author><style face="normal" font="default" size="100%">Bhosale, Vivek</style></author><author><style face="normal" font="default" size="100%">Srivastava, Mrigank</style></author><author><style face="normal" font="default" size="100%">Mugale, Madhav Nilakanth</style></author><author><style face="normal" font="default" size="100%">Pandey, C. P.</style></author><author><style face="normal" font="default" size="100%">Khan, Shaziya</style></author><author><style face="normal" font="default" size="100%">Katiyar, Shivani</style></author><author><style face="normal" font="default" size="100%">Raj, Desh</style></author><author><style face="normal" font="default" size="100%">Ishteyaque, Sharmeen</style></author><author><style face="normal" font="default" size="100%">Khanka, Sonu</style></author><author><style face="normal" font="default" size="100%">Rani, Ankita</style></author><author><style face="normal" font="default" size="100%">Promila</style></author><author><style face="normal" font="default" size="100%">Sharma, Jyotsna</style></author><author><style face="normal" font="default" size="100%">Seth, Anuradha</style></author><author><style face="normal" font="default" size="100%">Dutta, Mukul</style></author><author><style face="normal" font="default" size="100%">Saurabh, Nishant</style></author><author><style face="normal" font="default" size="100%">Veerapandian, Murugan</style></author><author><style face="normal" font="default" size="100%">Venkatachalam, Ganesh</style></author><author><style face="normal" font="default" size="100%">Bansal, Deepak</style></author><author><style face="normal" font="default" size="100%">Gupta, Dinesh</style></author><author><style face="normal" font="default" size="100%">Halami, Prakash M.</style></author><author><style face="normal" font="default" size="100%">Peddha, Muthukumar Serva</style></author><author><style face="normal" font="default" size="100%">Veeranna, Ravindra P.</style></author><author><style face="normal" font="default" size="100%">Pal, Anirban</style></author><author><style face="normal" font="default" size="100%">Singh, Ranvijay Kumar</style></author><author><style face="normal" font="default" size="100%">Anandasadagopan, Suresh Kumar</style></author><author><style face="normal" font="default" size="100%">Karuppanan, Parimala</style></author><author><style face="normal" font="default" size="100%">Rahman, Syed Nasar</style></author><author><style face="normal" font="default" size="100%">Selvakumar, Gopika</style></author><author><style face="normal" font="default" size="100%">Venkatesan, Subramanian</style></author><author><style face="normal" font="default" size="100%">Karmakar, Malay Kumar</style></author><author><style face="normal" font="default" size="100%">Sardana, Harish Kumar</style></author><author><style face="normal" font="default" size="100%">Kothari, Anamika</style></author><author><style face="normal" font="default" size="100%">Parihar, Devendra Singh</style></author><author><style face="normal" font="default" size="100%">Thakur, Anupma</style></author><author><style face="normal" font="default" size="100%">Saifi, Anas</style></author><author><style face="normal" font="default" size="100%">Gupta, Naman</style></author><author><style face="normal" font="default" size="100%">Singh, Yogita</style></author><author><style face="normal" font="default" size="100%">Reddu, Ritu</style></author><author><style face="normal" font="default" size="100%">Gautam, Rizul</style></author><author><style face="normal" font="default" size="100%">Mishra, Anuj</style></author><author><style face="normal" font="default" size="100%">Mishra, Avinash</style></author><author><style face="normal" font="default" size="100%">Gogeri, Iranna</style></author><author><style face="normal" font="default" size="100%">Rayasam, Geethavani</style></author><author><style face="normal" font="default" size="100%">Padwad, Yogendra</style></author><author><style face="normal" font="default" size="100%">Patial, Vikram</style></author><author><style face="normal" font="default" size="100%">Hallan, Vipin</style></author><author><style face="normal" font="default" size="100%">Singh, Damanpreet</style></author><author><style face="normal" font="default" size="100%">Tirpude, Narendra</style></author><author><style face="normal" font="default" size="100%">Chakrabarti, Partha</style></author><author><style face="normal" font="default" size="100%">Maity, Sujay Krishna</style></author><author><style face="normal" font="default" size="100%">Ganguly, Dipyaman</style></author><author><style face="normal" font="default" size="100%">Sistla, Ramakrishna</style></author><author><style face="normal" font="default" size="100%">Balthu, Narender Kumar</style></author><author><style face="normal" font="default" size="100%">Kumar, Kiran A.</style></author><author><style face="normal" font="default" size="100%">Ranjith, Siva</style></author><author><style face="normal" font="default" size="100%">Kumar, B. Vijay</style></author><author><style face="normal" font="default" size="100%">Jamwal, Piyush Singh</style></author><author><style face="normal" font="default" size="100%">Wali, Anshu</style></author><author><style face="normal" font="default" size="100%">Ahmed, Sajad</style></author><author><style face="normal" font="default" size="100%">Chouhan, Rekha</style></author><author><style face="normal" font="default" size="100%">Gandhi, Sumit G.</style></author><author><style face="normal" font="default" size="100%">Sharma, Nancy</style></author><author><style face="normal" font="default" size="100%">Rai, Garima</style></author><author><style face="normal" font="default" size="100%">Irshad, Faisal</style></author><author><style face="normal" font="default" size="100%">Jamwal, Vijay Lakshmi</style></author><author><style face="normal" font="default" size="100%">Paddar, Masroor Ahmad</style></author><author><style face="normal" font="default" size="100%">Khan, Sameer Ullah</style></author><author><style face="normal" font="default" size="100%">Malik, Fayaz</style></author><author><style face="normal" font="default" size="100%">Ghosh, Debashish</style></author><author><style face="normal" font="default" size="100%">Thakkar, Ghanshyam</style></author><author><style face="normal" font="default" size="100%">Barik, S. K.</style></author><author><style face="normal" font="default" size="100%">Tripathi, Prabhanshu</style></author><author><style face="normal" font="default" size="100%">Satija, Yatendra Kumar</style></author><author><style face="normal" font="default" size="100%">Mohanty, Sneha</style></author><author><style face="normal" font="default" size="100%">Khan, Md Tauseef</style></author><author><style face="normal" font="default" size="100%">Subudhi, Umakanta</style></author><author><style face="normal" font="default" size="100%">Sen, Pradip</style></author><author><style face="normal" font="default" size="100%">Kumar, Rashmi</style></author><author><style face="normal" font="default" size="100%">Bhardwaj, Anshu</style></author><author><style face="normal" font="default" size="100%">Gupta, Pawan</style></author><author><style face="normal" font="default" size="100%">Sharma, Deepak</style></author><author><style face="normal" font="default" size="100%">Tuli, Amit</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, Saumya Ray</style></author><author><style face="normal" font="default" size="100%">Krishnamurthi, Srinivasan</style></author><author><style face="normal" font="default" size="100%">Prakash, L.</style></author><author><style face="normal" font="default" size="100%">Rao, V. Ch</style></author><author><style face="normal" font="default" size="100%">Singh, B. N.</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Arvindkumar</style></author><author><style face="normal" font="default" size="100%">Chaurasiya, Meera</style></author><author><style face="normal" font="default" size="100%">Bhadange, Mayuri</style></author><author><style face="normal" font="default" size="100%">Likhitkar, Bhagyashree</style></author><author><style face="normal" font="default" size="100%">Mohite, Sharada</style></author><author><style face="normal" font="default" size="100%">Patil, Yogita</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Pandya, Vaibhav</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin</style></author><author><style face="normal" font="default" size="100%">Patil, Amita</style></author><author><style face="normal" font="default" size="100%">Samson, Rachel</style></author><author><style face="normal" font="default" size="100%">Vare, Tejas</style></author><author><style face="normal" font="default" size="100%">Dharne, Mahesh</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Mahajan, Sachin</style></author><author><style face="normal" font="default" size="100%">Paranjape, Shilpa</style></author><author><style face="normal" font="default" size="100%">Sastry, G. Narahari</style></author><author><style face="normal" font="default" size="100%">Kalita, Jatin</style></author><author><style face="normal" font="default" size="100%">Phukan, Tridip</style></author><author><style face="normal" font="default" size="100%">Manna, Prasenjit</style></author><author><style face="normal" font="default" size="100%">Romi, Wahengbam</style></author><author><style face="normal" font="default" size="100%">Bharali, Pankaj</style></author><author><style face="normal" font="default" size="100%">Ozah, Dibyajyoti</style></author><author><style face="normal" font="default" size="100%">Sahu, RaviKumar</style></author><author><style face="normal" font="default" size="100%">Dutta, Prachurjya</style></author><author><style face="normal" font="default" size="100%">Singh, Moirangthem Goutam</style></author><author><style face="normal" font="default" size="100%">Gogoi, Gayatri</style></author><author><style face="normal" font="default" size="100%">Tapadar, Yasmin Begam</style></author><author><style face="normal" font="default" size="100%">Babu, Elapavalooru V. S. S. K.</style></author><author><style face="normal" font="default" size="100%">Sukumaran, Rajeev K.</style></author><author><style face="normal" font="default" size="100%">Nair, Aishwarya R.</style></author><author><style face="normal" font="default" size="100%">Puthiyamadam, Anoop</style></author><author><style face="normal" font="default" size="100%">Valappil, Prajeesh Kooloth</style></author><author><style face="normal" font="default" size="100%">Prasannakumari, Adrash Velayudhan Pillai</style></author><author><style face="normal" font="default" size="100%">Chodankar, Kalpana</style></author><author><style face="normal" font="default" size="100%">Damare, Samir</style></author><author><style face="normal" font="default" size="100%">Agrawal, Ved Varun</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Kumardeep</style></author><author><style face="normal" font="default" size="100%">Agrawal, Anurag</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shantanu</style></author><author><style face="normal" font="default" size="100%">Dash, Debasis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys</style></title><secondary-title><style face="normal" font="default" size="100%">Computers in Biology and Medicine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BBV152</style></keyword><keyword><style  face="normal" font="default" size="100%">Covaxin</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Ensemble methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">146</style></volume><pages><style face="normal" font="default" size="100%">105419</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the vaccine effectiveness. Asymptomatic breakthrough infections have been a major problem in assessing vaccine effectiveness in populations globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines since whole virion vaccines generate antibodies against all the viral proteins. Here, we show how a statistical and machine learning (ML) based approach can be used to discriminate between SARS-CoV-2 infection and immune response to an inactivated whole virion vaccine (BBV152, Covaxin). For this, we assessed serial data on antibodies against Spike and Nucleocapsid antigens, along with age, sex, number of doses taken, and days since last dose, for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, our ensemble ML model classified 724 to be infected. For method validation, we determined the relative ability of a random subset of samples to neutralize Delta versus wild-type strain using a surrogate neutralization assay. We worked on the premise that antibodies generated by a whole virion vaccine would neutralize wild type more efficiently than delta strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, neutralization against Delta strain was more effective, indicating infection. We found 71.8% subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period. Our approach will help in real-world vaccine effectiveness assessments where whole virion vaccines are commonly used.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	6.698&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bansode, Sneha</style></author><author><style face="normal" font="default" size="100%">Singh, Pawan Kumar</style></author><author><style face="normal" font="default" size="100%">Tellis, Meenakshi</style></author><author><style face="normal" font="default" size="100%">Chugh, Anita</style></author><author><style face="normal" font="default" size="100%">Deshmukh, Narendra</style></author><author><style face="normal" font="default" size="100%">Gupta, Mahesh</style></author><author><style face="normal" font="default" size="100%">Verma, Savita</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Dhruva</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comprehensive molecular and clinical investigation of approved Anti-HCV drugs repurposing against SARS-CoV-2 infection: a glaring gap between benchside and bedside medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antiviral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">daclatasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">ledipasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">sofosbuvir</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">515</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation. In this report, the anti-SARS-CoV-2 potential of anti-HCV drugs such as daclatasvir (DCV) or ledipasvir (LDP) in combination with sofosbuvir (SOF) was evaluated. The binding mode and higher affinity of these molecules with RNA-dependent-RNA-polymerase of SARS-CoV-2 were apparent by computational analysis. In vitro anti-SARS-CoV-2 activity depicted that SOF/DCV and SOF/LDP combination has IC50 of 1.8 and 2.0 mu M, respectively, comparable to remdesivir, an approved drug for COVID-19. Furthermore, the clinical trial was conducted in 183 mild COVID-19 patients for 14 days to check the efficacy and safety of SOF/DCV and SOF/LDP compared to standard of care (SOC) in a parallel-group, hybrid, individually randomized, controlled clinical study. The primary outcomes of the study suggested no significant difference in negativity after 3, 7 and 14 days in both treatments. None of the patients displayed any worsening in the disease severity, and no mortality was observed in the study. Although, the post hoc exploratory analysis indicated significant normalization of the pulse rate showed in SOF/DCV and SOF/LDP treatment vs. SOC. The current study highlights the limitations of bench side models in predicting the clinical efficacy of drugs that are planned for repurposing.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.961&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ambekar, Aditi S.</style></author><author><style face="normal" font="default" size="100%">Naredi, Nikita</style></author><author><style face="normal" font="default" size="100%">Malakar, Dipankar</style></author><author><style face="normal" font="default" size="100%">Vashum, Y.</style></author><author><style face="normal" font="default" size="100%">Misra, Pratibha</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Early and advanced glycation end product analysis from women with PCOS on metformin</style></title><secondary-title><style face="normal" font="default" size="100%">Reproductive Biology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Carboxymethyl lysine</style></keyword><keyword><style  face="normal" font="default" size="100%">Fructosamine</style></keyword><keyword><style  face="normal" font="default" size="100%">fructose</style></keyword><keyword><style  face="normal" font="default" size="100%">glucose</style></keyword><keyword><style  face="normal" font="default" size="100%">Pentosidine</style></keyword><keyword><style  face="normal" font="default" size="100%">Polycystic ovary syndrome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">25</style></volume><pages><style face="normal" font="default" size="100%">100993</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	In this cross-sectional study, we have analyzed advanced glycation end products (AGEs) in the plasma and follicular fluid of women with polycystic ovary syndrome (PCOS) taking metformin during in vitro fertilization (IVF) and control women undergoing IVF. Glucose, fructose, fructosamine, carboxymethyl lysine/ arginine (CML/R) proteins, and pentosidine were measured in the plasma and paired follicular fluid. Glycated proteins were characterized by mass spectrometry. Fasting serum glucose and fructosamine were comparable; however, follicular fluid glucose and fructosamine were higher in the PCOS group, and other AGEs remained unaltered. Fructose was lower in both serum and follicular fluid from the PCOS group. A positive correlation between some of these AGEs and sugars estimated was observed. Glucose and fructosamine in the follicular fluid correlated with the antral follicle count. The number of glycated peptides identified in the PCOS group by mass spectrometry was more. Glycated K75, K402 amino acid residues of albumin were detected in the PCOS group only. Additionally, some proteins involved in steroidogenesis and oocyte maturation as well as transporters, and extracellular matrix proteins, were found to be glycated in the PCOS group, which may affect their function. Elevated glucose and fructosamine in the follicular fluid of the PCOS group may contribute to abnormal folliculogenesis. The glycation of albumin should be validated in more samples to be considered as a marker for PCOS diagnosis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	2.5&lt;/p&gt;
</style></custom4></record></records></xml>